TEVA Q3 2022 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.6B-7.5% YoY

Gross Profit

$1.7B46.4% margin

Operating Income

$419M11.7% margin

Net Income

$56M1.6% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

-5.0%

Cash Flow

Operating Cash Flow

$543M

Free Cash Flow

$421M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$44.3B

Total Liabilities

$34.7B

Stockholders' Equity

$8.8B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.6B	$3.9B	-7.5%
Gross Profit	$1.7B	$1.8B	-7.0%
Operating Income	$419M	$623M	-32.7%
Net Income	$56M	$292M	-80.8%

Revenue Segments

Product

$3.0B84%

Distribution Service

$383M11%

Product and Service, Other

$139M4%

License

$52M1%

Geographic Segments

North America Segment

$1.8B54%

Europe Segment

$1.1B32%

International Markets

$475M14%